870837-18-6

Basic information

• Product Name: 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde
• Synonyms: 3-methoxy-4-(4-methylimidazole)benzaldehyd;3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZALDEHYDE;3-METHOXY-4-(4-METHYL-IMIDAZOL-1-YL)-BENZALDEHYDE;3-Methoxy-4-(4-methyl-1H-imidazol-1-yl);Benzaldehyde, 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)-
• CAS NO: 870837-18-6
• Molecular Formula: C₁₂H₁₂N₂O₂
• Molecular Weight: 216.24
• Mol File: 870837-18-6.mol

Chemical Properties

• Boiling Point: 415.094 °C at 760 mmHg
• Flash Point: 204.842 °C
• Appearance: /
• Density: 1.16
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.43±0.61(Predicted)
• CAS DataBase Reference: 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde(870837-18-6)
• EPA Substance Registry System: 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde(870837-18-6)

Safety Data

• Hazardous Substances Data: 870837-18-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde is utilized as a key building block in the synthesis of new therapeutic agents for a variety of medical conditions. Its distinctive chemical structure allows for the creation of compounds with potential applications in treating different diseases.
Used in Anti-Inflammatory Applications:
In the field of medicine, 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde is studied for its potential as an anti-inflammatory agent. Its properties may contribute to the management of inflammation, which is a common factor in numerous health conditions.
Used in Anti-Cancer Applications:
3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde is also being investigated for its potential as an anti-cancer agent. 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde's structure and properties suggest that it may have the ability to target and combat cancer cells, offering a new avenue for cancer treatment.
Further research and development of 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde may pave the way for the discovery of new drug candidates with significant clinical applications, particularly in the areas of inflammation and cancer treatment.

InChI:InChI=1/C12H12N2O2/c1-9-6-14(8-13-9)11-4-3-10(7-15)5-12(11)16-2/h3-8H,1-2H3

Upstream product

• 700834-18-0 4-formylamino-3-methoxybenzoic acid methyl ester 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 870837-20-0 4-[formyl-(2-oxopropyl)amino]-3-methoxybenzoic acid methyl ester 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 
• 1280150-10-8 3-fluoro-4-(4-methyl-1H-imidazol-1-yl)benzonitrile 
• 1243204-92-3 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzonitrile 
• 243128-37-2 4-fluoro-3-methoxybenzonitrile 
• 64248-62-0 3,4-Difluorobenzonitrile 
• 822-36-6 4-methyl-1H-imidazole 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 870837-21-1 3-methoxy-4-(4-methylimidazol-1-yl)benzoic acid methyl ester 

Downstream Products

• 937397-34-7 (Z)-(S)-4-[(S)-1-(2,6-difluoropyridin-3-yl)ethyl]-2-[1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene]-6-methylmorpholin-3-one 
• 1096710-83-6 C₃₁H₃₅FN₄O₄ 
• 1314875-06-3 C₂₂H₂₀F₃N₅O₂ 
• 1314873-95-4 C₂₂H₁₈F₃N₅O₂ 
• 870850-40-1 (E)-1-(4-(2-carboxy-5-chloropent-1-en-1-yl)-2-methoxyphenyl)-4-methyl-1H-imidazol-3-ium 2,2,2-trifluoroacetate 
• 1352130-00-7 (S,E)-5-chloro-N-(2-hydroxy-1-(3,4,5-trifluorophenyl)ethyl)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)pentanamide 
• 870852-75-8 (S,E)-1-(2-hydroxy-1-(3,4,5-trifluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)piperidin-2-one 
• 1352130-01-8 (S,E)-1-(2-(aminooxy)-1-(3,4,5-trifluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)piperidin-2-one 
• 870843-26-8 tert-butyl 5-chloro-2-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}valerate 

Relevant articles and documents

Synthesis of the γ-Secretase Modulator MK-8428

The synthesis of the γ-secretase modulator MK-8428 (1) is described. The synthesis is highlighted by an enzyme-catalyzed reaction to access 3,4,5-trifluoro-(S)-phenylglycine, a 1-pot activation/displacement/deprotection sequence to introduce the aminooxy functionality and a dehydrative intramolecular cyclization under mild conditions to form the oxadiazine heterocycle of 1. In situ reaction monitoring was employed to understand the deleterious role of water during the formation of a methanesulfonate ester in the 1-pot activation/displacement/deprotection sequence.

Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys

Abstract Synthesis and SAR studies of novel triazolobenzazepinones as gamma secretase modulators (GSMs) are presented in this communication. Starting from our azepinone leads, optimization studies toward improving central lowering of Aβ42 led to the discovery of novel benzo-fused azepinones. Several benzazepinones were profiled in vivo and found to lower brain Aβ42 levels in Sprague Dawley rats and transgenic APP-YAC mice in a dose-dependent manner after a single oral dose. Compound 34 was further progressed into a pilot study in our cisterna-magna-ported rhesus monkey model, where we observed robust lowering of CSF Aβ42 levels.

Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond

The most prevalent leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is associated with Parkinson's disease (PD). It enhances kinase activity and has been identified in both familial and sporadic cases. Kinase activity was reported to be required for LRRK2 mutants to exert their toxic effects. Hence LRRK2 kinase inhibition may be a promising therapeutic target for PD. Here we report on the discovery and characterization of indolinone based LRRK2 inhibitors. Indolinone 15b, the most potent and selective inhibitor of the present series, is characterized by an IC50of 15 nM against wild-type LRRK2 and 10 nM against the LRRK2 G2019S mutant, respectively. Compound 15b was further evaluated in a kinase panel including 46 human protein kinases and in a zebrafish embryo phenotype assay, which enabled toxicity determination in whole organisms.

Triazoloamides as potent γ-secretase modulators with reduced hERG liability

Synthesis and SAR studies of novel aryl triazoles as gamma secretase modulators (GSMs) are presented in this communication. Starting from our aryl triazole leads, optimization studies were continued and the series progressed towards novel amides and lactams. Triazole 57 was identified as the most potent analog in this series, displaying single-digit nanomolar Aβ42 IC 50 in cell-based assays and reduced affinity for the hERG channel.

Synthesis of a potent photoreactive acidic γ-secretase modulator for target identification in cells

Supramolecular self-assembly of amyloidogenic peptides is closely associated with numerous pathological conditions. For instance, Alzheimers disease (AD) is characterized by abundant amyloid plaques originating from the proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Compounds named γ-secretase modulators (GSMs) can shift the substrate cleavage specificity of γ-secretase toward the production of non-amyloidogenic, shorter Aβ fragments. Herein, we describe the synthesis of highly potent acidic GSMs, equipped with a photoreactive diazirine moiety for photoaffinity labeling. The probes labeled the N-terminal fragment of presenilin (the catalytic subunit of γ-secretase), supporting a mode of action involving binding to γ-secretase. This fundamental step toward the elucidation of the molecular mechanism governing the GSM-induced shift in γ-secretase proteolytic specificity should pave the way for the development of improved drugs against AD.

Synthesis of a potent photoreactive acidic γ-secretase modulator for target identification in cells

Supramolecular self-assembly of amyloidogenic peptides is closely associated with numerous pathological conditions. For instance, Alzheime?s disease (AD) is characterized by abundant amyloid plaques originating from the proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Compounds named γ-secretase modulators (GSMs) can shift the substrate cleavage specificity of γ-secretase toward the production of non-amyloidogenic, shorter Aβ fragments. Herein, we describe the synthesis of highly potent acidic GSMs, equipped with a photoreactive diazirine moiety for photoaffinity labeling. The probes labeled the N-terminal fragment of presenilin (the catalytic subunit of γ-secretase), supporting a mode of action involving binding to γ-secretase. This fundamental step toward the elucidation of the molecular mechanism governing the GSM-induced shift in γ-secretase proteolytic specificity should pave the way for the development of improved drugs against AD.

NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the mean

Quinazolinones as γ-secretase modulators

Synthesis, SAR and evaluation of styrenyl quinazolinones as novel gamma secretase modulators are presented in this communication. Starting from literature and in-house leads we evaluated a range of quinazolinones which showed good modulation of γ-secretas

Triazoles as γ-secretase modulators

Synthesis, SAR, and evaluation of aryl triazoles as novel gamma secretase modulators (GSMs) are presented in this communication. Starting from the literature and in-house leads, we evaluated a range of five-membered heterocycles as replacements for olefin

NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het1, R1, R2, A1, A2, A3, A4, L1, and L2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma sec